Drawing for RHEACELL

USPTO serial 79229551

RHEACELL

Reviewed by CopyMark Law Group

Reg. 5694020Status 739Registered
Filing date
Status date
Registration date
Mar 12, 2019
Examiner
VAGHANI, MAYUR C
Law office
Historical data usage

What this means

This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.

Need help with RHEACELL?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Claudia W. Stangle

Claudia W. Stangle Leydig, Voit & Mayer, Ltd.Two Prudential Plaza, 180 N. Stetson AveSuite 4900Chicago, IL 60601

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical [ and veterinary ] preparations for treatment of skin diseases; pharmaceutical [ and veterinary ] preparations for the treatment of vertigo; pharmaceutical [ and veterinary ] preparations for treatment of nausea; [ pharmaceutical and veterinary preparations for treatment of vomiting; pharmaceutical and veterinary preparations for treatment of migraine; ] pharmaceutical [ and veterinary ] preparations for treatment of disease and disorders of the respiratory system, the gastrointestinal system, the endocrine system, the cardiovascular system, the nervous system, the musculoskeletal system, [ the urinary system, ] the integumentary system [, and the reproductive system ]; pharmaceutical [ and veterinary ] preparations for treatment of blood diseases and disorders; pharmaceutical [ and veterinary ] preparations, namely, antibiotics, immune suppressants, anti-inflammatory pharmaceuticals; pharmaceutical [ and veterinary ] preparations for wound healing; pharmaceutical [and veterinary preparations for anti-aging, namely, stem cells for medical and aesthetic purposes, [ fibroblasts for medical and aesthetic purposes, ] surgical tissue implants obtained from stem cells [ , surgical tissue implants obtained from fibroblasts ]ACTIVE—
042Scientific and technological services, namely medical and scientific research services in the fields of regenerative medicine and tissue engineering, scientific research, testing and analysis services in the field of regenerative medicine and tissue engineering, consulting services relating to scientific research in the fields of regenerative medicine and tissue engineering, providing information on medical and scientific research on pharmaceutical products, providing information in the form of expert reports relating to scientific research in the fields of regenerative medicine and tissue engineering; Industrial analysis, namely chemical analysis; research services, namely laboratory research services relating to pharmaceuticals, medical, biomedical and stem cell research in the field of regenerative medicine and tissue engineering, scientific and medical research and development for medical purposes in the field of regenerative medicine and tissue engineering, research and development services relating to new products for others, research in the field of biotechnology, research in the field of gene therapy, research and development in the field of immunology, research and development in the field of antibodies, research and development in the field of antibody technology, research and development in the field of bacteriology, research and development in the field of gene expression systems, research and development in the field of vaccines, pharmaceutical research and development services, research and development services in the field of biotechnologyACTIVE—
044Medical servicesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
May 14, 2026NREPNEW REPRESENTATIVE AT IB RECEIVED—
Mar 7, 2026INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Jul 7, 2025NA75NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED—
Jul 7, 2025C75AREGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.—
Jun 30, 2025APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Mar 27, 2025ES75TEAS SECTION 71 & 15 RECEIVED—
Mar 12, 2024REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Jan 4, 2024RNWLINTERNATIONAL REGISTRATION RENEWED—
Jul 19, 2019FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Jul 1, 2019FICSFINAL DISPOSITION NOTICE SENT TO IB—
Jul 1, 2019FIMPFINAL DISPOSITION PROCESSED—
Jun 12, 2019FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Mar 12, 2019R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 25, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 25, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 5, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 13, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 24, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 23, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 23, 2018ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Oct 19, 2018ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 19, 2018REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Sep 10, 2018CNFRFINAL REFUSAL MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Sep 10, 2018CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Aug 21, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 21, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 21, 2018ALIEASSIGNED TO LIE—
Aug 1, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 8, 2018RFNTREFUSAL PROCESSED BY IB—
May 23, 2018RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
May 23, 2018RFRRREFUSAL PROCESSED BY MPU—
May 19, 2018RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
May 18, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 17, 2018DOCKASSIGNED TO EXAMINER—
Apr 4, 2018MAFRAPPLICATION FILING RECEIPT MAILED—
Mar 31, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 29, 2018SDRCSN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB—

Frequently asked questions

Related guidance